First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor

Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis

(2012) Akira Tokumura et al.   International Journal of Medical Sciences

Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma

(2011) Flavia V. Castelino et al.   ARTHRITIS AND RHEUMATISM

LPA Receptors: Subtypes and Biological Actions

(2010) Ji Woong Choi et al.   Annual Review of Pharmacology and Toxicology

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

(2010) JS Swaney et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

(2010) J. S. Swaney et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

(2010) J. Chun et al.   PHARMACOLOGICAL REVIEWS

Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts

(2010) Z. Yin et al.   RHEUMATOLOGY